Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells

International Journal of Cancer

Volumn 75, Issue 6, 1998, Pages 933-940

  Blagosklonny, Mikhail V ^a   El Deiry, Wafik S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOMYCIN C; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROBLAST; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DEATH; COMBINED MODALITY THERAPY; DNA DAMAGE; DOXORUBICIN; GENETIC VECTORS; HUMANS; MICE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031892456     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3     Document Type: Article

References (25)

1. BLAGOSKLONNY, M.V., Loss of function and p53 protein stabilization. Oncogene, 15, 1889-1893 (1997).
2. BLAWSKLONNY, M.V. and EL-DEIRY, W.S., In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer, 67, 386-392 (1996).
3. CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD, C.C. HOOPER, M.L. and WYLLIE, A.H., Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362, 849-852 (1993).
4. EL-DEIRY, W.S., TOKINO, T., VECULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell. 75, 817-825 (1993).
5. FAN, S., SMITH, M.L., RIVET, D.J., DUBA D., ZHAN, Q., KOHN, K.W., FORNACE, A.J. and O'CONNOR, P.M., Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
6. FUJIWARA, T., GRIMM, E.A., MUKHOPADHYAY, T., ZHANG, W.-W., OWENSCHAUB, L.B. and ROTH, J.A., Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291 (1994).
7. GJERSET, R., TURLA, S., SOBOL, R., SCALISE, J., MERCOLA, D., COLLINS, H. and HOPKINS, P., Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinogenesis, 14, 275-285 (1995).
8. HAWKINS, D., DEMERS, W., and GALLOWAY, D., Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
9. KATAYOSE, D., GUDAS, J., NGUYEN, H., SRIVASTAVA, S., COWAN, K.H. and SETH, P., Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res., 1, 889-897 (1995).
10. LABRECQUE, S., and MATLASHEWSKI, G.J., Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene, 11, 387-392 (1995).
11. LEVINE, A.J., p53. the cellular gatekeeper for growth and division. Cell, 88, 323-331 (1997).
12. LOWE, S.W., RULEY, H.E., JACKS, T., and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
13. MALCOMSON, R.D.G., OREN, M., WYLLIE, A.H., and HARRISON, D.J., p53-independent death and p53-induced protection against apoptosis in fibroblasta treated with chemotherapeutic drugs. Brit. J. Cancer, 72, 952-957 (1995).
14. O'CONNOR, P.M. and 12 OTHERS, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-4301 (1997).
15. POLYAK, K., WALDMAN, T., HE, T.C., KINZLER, K.W. and VOGELSTEIN, B., Genetic determinants of p53-induced apoptosis and growth arrest. Genes Develop., 10, 1945-1952 (1996).
16. POWELL, S.N., DEFRANK, J.S., CONNELL, P., EOGAN, M., PREFFER, F., DOMBKOWSKI, D., TANG, W. and FRIEND, S., Differential sensitivity of p53 (-) and p53 (+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res., 55, 1643-1648 (1995).
17. SETH, P., KATAYOSE, D., LI, Z., KIM, M., WERSTO, R., CRAIG, C., SHANMUGAM, N., OHRI, E., MUDAHSAR, B., RAKKAR, A.N.S., KODALI, P., and COWAN, K., A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther, 4, (1997).
18. SLICHENMYER, W.J., NELSON, W.G., SLEBOS, R.J., and KASTAN, M.B., Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53, 4164-4168 (1993).
19. SMITH, M.L., CHEN, I.T., ZHAN, Q., Q'CONNOR, P.M. and FORNACE, A.J., Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage. Oncogene. 10, 1053-1059 (1995).
20. TSANG, N.M., NAGASAWA, H., LI, C. and LITTLE, J.B., Abrogation of p53 function by transfection of HPV 16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene, 10, 2403-2408 (1995).
21. VIKHANSKAYA, F., D'INCALCI, M. and BROGGINI, M., Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and Waf/Cip1 genes. Int. J. Cancer. 61, 397-401 (1995).
22. WAHL, A.F., DONALDSON, K.L., FAIRCHILD, C., LEE, F.Y.F., FOSTER, S.A., DEMERS, G.W., and GALLOWAY, D.A., Loss of normal p53 function confers sensitization totaxol by increasing G2/M arrest and apoptosis. Nature Med., 2, 72-79 (1996).
23. WU, G.S. and EL-DEIRY, W.S., p53 and chemosensitivity. Nature Med., 2, 255-256 (1996).
24. XU, C., MEIKRANTZ, W., SCHLEGEL, R. and SAGER, R., The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc. nat. Acad. Sci. (Wash.), 92, 7829-7833 (1995).
25. YANG, B., ESHLEMAN, J.R., BERGER, N.A. and MARKOWITZ, S.D., Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clinical Cancer Res., 2, 1649-1657 (1996).